Evaluating The Association Between Serum Hsp۲۷ Antibody and Hypertension in Patients without Underlying Cardiovascular Disease

Publish Year: 1402
نوع سند: مقاله ژورنالی
زبان: English
View: 155

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_JCTM-11-1_002

تاریخ نمایه سازی: 20 فروردین 1402

Abstract:

Introduction: An association between heat shock protein ۲۷ (Hsp۲۷) antigen with cardiovascular risk factors has been shown previously. Furthermore, higher levels of serum anti-HSP۲۷ antibodies are also related to higher cardiovascular morbidity and mortality. In the current study, we looked at the relationship between serum Hsp۲۷ antibodies and hypertension, as an important cardiovascular risk factor, in individuals without evidence of cardiovascular disease (CVD).Methods: A sub-population of hypertensive patients (HTN+) without underlying CVD were recruited from the Mashhad stroke and atherosclerosis heart disease (MASHAD) study to assess the association between serum Hsp۲۷ antibodies and hypertension; independent of other cardiovascular risk factors. A total of ۱۵۹۹ people were studied of whom ۲۸۸ individuals had hypertension and ۱۳۱۱ were used as controls (HTN-).Results: Mean serum Hsp۲۷ antibody titers were ۰.۲۰ (۰.۲۷) OD in the whole population sample and was not significantly different in the normotensive (HTN-) compared to HTN+ individuals with different degrees of hypertension.Conclusion: There were no significant associations between serum anti-Hsp۲۷ concentrations and either the presence or severity of hypertension. Future studies are warranted to explore the association of anti-Hsp۲۷ antibody and antigen levels and other cardiovascular risk factors.

Keywords:

Heat shock protein ۲۷ antibody , Hypertension , Cardiovascular Disease

Authors

Mahdieh Khazaee

Immunology Research Center, BuAli Research Institute, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Mahdi Taheri Bonakdar

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Mahmoud Ebrahimi

Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.

Mohammad Reza Aarpazhooh

Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.

Hamideh Ghazizadeh

International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Mohsen Mouhebati

Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Maryam shahi

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Fatemeh Haji shamsaei

Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.

Zahra Alizadeh hassani

Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.

Faezeh Ghasemi

Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad,Iran.

Maryam Tayefi

Norwegian Center for E-Health Research, University Hospital of North Norway, Tromsø, Norway.

Shima Tavallaie

Department of Biochemistery and Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Amirhosein Sahebkar

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Gordon A. Ferns

Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN۱ ۹PH, UK.

Seyed Mohammad Reza Parizadeh

Metabolic Syndrome Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Majid Ghayour-Mobarhan

International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Ferns G, Shams S, Shafi S. Heat shock protein ۲۷: ...
  • Mehlen P, Hickey E, Weber LA, Arrigo AP. Large unphosphorylated ...
  • Ciocca DR, Oesterreich S, Chamness GC, MCGuire WL, Fuqua SA. ...
  • Akamatsu S, Nakajima K, Ishisaki A, Matsuno H, Tanabe K, ...
  • Hirade K, Kozawa O, Tanabe K, Niwa M, Matsuno H, ...
  • Garrido C, Bruey JM, Fromentin A, Hammann A, Patrick Arrigo ...
  • Charette SJ, Lavoie JN, Lambert H, Landry J. Inhibition of ...
  • Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, ...
  • Loktionova SA, Kabakov AE. Phosphatase inhibitors prevent HSP۲۷ dephosphorylation, destruction ...
  • Loktionova SA, Kabakov AE. Protein phosphatase inhibitors and heat preconditioning ...
  • Hirano S, Rees RS, Yancy SL, Welsh MJ, Remick DG, ...
  • Aghasizadeh M, Samadi S, Sahebkar A, Miri‐Moghaddam E, Esmaily H, ...
  • Arata S, Hamaguchi S, Nose K. Effects of the overexpression ...
  • Arrigo AP, Virot S, Chaufour S, Firdaus W, Kretz-Remy C, ...
  • De AK, Kodys KM, Yeh BS, Miller-Graziano C. Exaggerated human ...
  • Chen Y, Ross BM, Currie RW. Heat shock treatment protects ...
  • Xu Q, Li DG, Holbrook NJ, Udelsman R. Acute hypertension ...
  • Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, ...
  • Wick G. The heat is on: heat-shock proteins and atherosclerosis. ...
  • Ghayour-Mobarhan M, Saber H, Ferns GA. The potential role of ...
  • Park KJ, Gaynor RB, Kwak YT. Heat shock protein ۲۷ ...
  • Makowski GS. Advances in clinical chemistry: Gulf Professional Publishing; ۲۰۰۵ ...
  • Tavallaie S, Rahsepar AA, Abdi H, Moohebati M, Moodi F, ...
  • Shams S, Shafi S, Bodman-Smith K, Williams P, Mehta S, ...
  • Pourghadamyari H, Moohebati M, Parizadeh SM, Falsoleiman H, Dehghani M, ...
  • Maki KC, Bays HE, Dicklin MR. Treatment options for the ...
  • Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SM, ...
  • Perloff D, Grim C, Flack J, Frohlich ED, Hill M, ...
  • Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, ...
  • Sahebkar A, Pourghadamyari H, Moohebati M, Parizadeh SM, Falsoleiman H, ...
  • Bell K, Twiggs J, Olin BR, Date IR. Hypertension: the ...
  • Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, ...
  • Ghayour-Mobarhan M, Rahsepar AA, Tavallaie S, Rahsepar S, Ferns GA. ...
  • Ghayour‐Mobarhan M, Sahebkar A, Parizadeh SM, Moohebati M, Tavallaie S, ...
  • Mouhebati M, Ghayour-Mobarhan M, Parizadeh S, Sahebkar A, Tavallaie S, ...
  • Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy ...
  • Hokanson JE, Austin MA. Plasma triglyceride level is a risk ...
  • KUNEŠ J, Poirier M, Tremblay J, Hamet P. Expression of ...
  • Pockley AG, De Faire U, Kiessling R, Lemne C, Thulin ...
  • Molvarec A, Prohászka Z, Nagy B, Szalay J, Füst G, ...
  • نمایش کامل مراجع